Life-science tools oligopoly: razor-blade consumable pull across the entire biopharma R&D stack. Paid per experiment regardless of which drug wins.
Research snapshot · Not reviewed
TMOThermo Fisher Scientific
Life-science tools, specialty diagnostics, proteomics, reagents
Open TMO in Robinhood ↗Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap194.52BSnapshot value
AI-bundled autonomous instruments (NVIDIA partnership DGX Spark / NeMo agentic workflows, 2H 2026); consolidation tailwind (Solventum purification/filtration $4.1B acquisition); recurring reagent revenue ~75% of proteomics market.
Research funding collapse (NIH indirect-cost cap, flat academic budgets); AI-coupling shifts factor-load toward AI trade; China softness; integration risk from M&A wave.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟡 Mixed · ins-$3.0M · 13F 16+/9- · short↑0.25
Snapshot · Not reviewed